Aptevo More Than Doubles After Favorable Results in Leukemia Study

Dow Jones

19 Jun

By Josh Beckerman

Aptevo Therapeutics shares bounced back from Tuesday's 52-week low, more than doubling Wednesday after the company reported favorable results for its lead drug candidate in an acute myeloid leukemia study.

Shares were recently up 114% to $6.03. Volume was over 115 million shares by Wednesday afternoon, compared with a 65-day average of about 275,000. The stock is down about 93% this year. Its 52-week low was $2.81.

The company reported data from a Phase 1b/2 trial evaluating mipletamig in combination with standard-of-care venetoclax and azacitidine for newly diagnosed patients with acute myeloid leukemia who are unfit for intensive chemotherapy.

The mipletamig triplet therapy delivered remissions in 85% of evaluable frontline AML patients, Aptevo said. No dose-limiting toxicities were observed among evaluable patients, it added.

Aptevo also announced an $8 million registered direct offering. It agreed to sell 2.465 million shares or pre-funded warrants and 12.325 million warrants at price of $3.25 per share and associated warrants.

The company is offering the securities pursuant to a registration statement filed Monday.

On Tuesday, Aptevo reported a standby equity-purchase agreement with Yorkville Advisors for up to $25 million.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

June 18, 2025 13:34 ET (17:34 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2544040839"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544040839\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2544040839?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-19 01:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544040839","market":"us","top_or_hot":-1,"title":"Aptevo More Than Doubles After Favorable Results in Leukemia Study","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares bounced back from Tuesday's 52-week low, more than doubling Wednesday after the company reported favorable results for its lead drug candidate in an acute myeloid leukemia study. \n</p>\n<p>\n  Shares were recently up 114% to $6.03. Volume was over 115 million shares by Wednesday afternoon, compared with a 65-day average of about 275,000. The stock is down about 93% this year. Its 52-week low was $2.81. \n</p>\n<p>\n  The company reported data from a Phase 1b/2 trial evaluating mipletamig in combination with standard-of-care venetoclax and azacitidine for newly diagnosed patients with acute myeloid leukemia who are unfit for intensive chemotherapy. \n</p>\n<p>\n  The mipletamig triplet therapy delivered remissions in 85% of evaluable frontline AML patients, Aptevo said. No dose-limiting toxicities were observed among evaluable patients, it added. \n</p>\n<p>\n  Aptevo also announced an $8 million registered direct offering. It agreed to sell 2.465 million shares or pre-funded warrants and 12.325 million warrants at price of $3.25 per share and associated warrants. \n</p>\n<p>\n  The company is offering the securities pursuant to a registration statement filed Monday. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/ONON\">On</a> Tuesday, Aptevo reported a standby equity-purchase agreement with Yorkville Advisors for up to $25 million. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 18, 2025 13:34 ET (17:34 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptevo More Than Doubles After Favorable Results in Leukemia Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptevo More Than Doubles After Favorable Results in Leukemia Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-06-19 01:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares bounced back from Tuesday's 52-week low, more than doubling Wednesday after the company reported favorable results for its lead drug candidate in an acute myeloid leukemia study. \n</p>\n<p>\n  Shares were recently up 114% to $6.03. Volume was over 115 million shares by Wednesday afternoon, compared with a 65-day average of about 275,000. The stock is down about 93% this year. Its 52-week low was $2.81. \n</p>\n<p>\n  The company reported data from a Phase 1b/2 trial evaluating mipletamig in combination with standard-of-care venetoclax and azacitidine for newly diagnosed patients with acute myeloid leukemia who are unfit for intensive chemotherapy. \n</p>\n<p>\n  The mipletamig triplet therapy delivered remissions in 85% of evaluable frontline AML patients, Aptevo said. No dose-limiting toxicities were observed among evaluable patients, it added. \n</p>\n<p>\n  Aptevo also announced an $8 million registered direct offering. It agreed to sell 2.465 million shares or pre-funded warrants and 12.325 million warrants at price of $3.25 per share and associated warrants. \n</p>\n<p>\n  The company is offering the securities pursuant to a registration statement filed Monday. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/ONON\">On</a> Tuesday, Aptevo reported a standby equity-purchase agreement with Yorkville Advisors for up to $25 million. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 18, 2025 13:34 ET (17:34 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APVO","symbol_name":"Aptevo Therapeutics Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2544040839","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544040839","pubTimestamp":1750268040,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Aptevo Therapeutics shares bounced back from Tuesday's 52-week low, more than doubling Wednesday after the company reported favorable results for its lead drug candidate in an acute myeloid leukemia study.Shares were recently up 114% to $6.03. Volume was over 115 million shares by Wednesday afternoon, compared with a 65-day average of about 275,000. The stock is down about 93% this year. Its 52-week low was $2.81.The company reported data from a Phase 1b/2 trial evaluating mipletamig in combination with standard-of-care venetoclax and azacitidine for newly diagnosed patients with acute myeloid leukemia who are unfit for intensive chemotherapy.The mipletamig triplet therapy delivered remissions in 85% of evaluable frontline AML patients, Aptevo said. No dose-limiting toxicities were observed among evaluable patients, it added.Aptevo also announced an $8 million registered direct offering. It agreed to sell 2.465 million shares or pre-funded warrants and 12.325 million warrants at price ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APVO":"Aptevo Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"白血病研究取得良好结果后，Aptevo的产量增加了一倍多","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APVO":0.9},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Aptevo Therapeutics shares bounced back from Tuesday's 52-week low, more than doubling Wednesday after the company reported favorable results for its lead drug candidate in an acute myeloid leukemia study. \n\n\n  Shares were recently up 114% to $6.03. Volume was over 115 million shares by Wednesday afternoon, compared with a 65-day average of about 275,000. The stock is down about 93% this year. Its 52-week low was $2.81. \n\n\n  The company reported data from a Phase 1b/2 trial evaluating mipletamig in combination with standard-of-care venetoclax and azacitidine for newly diagnosed patients with acute myeloid leukemia who are unfit for intensive chemotherapy. \n\n\n  The mipletamig triplet therapy delivered remissions in 85% of evaluable frontline AML patients, Aptevo said. No dose-limiting toxicities were observed among evaluable patients, it added. \n\n\n  Aptevo also announced an $8 million registered direct offering. It agreed to sell 2.465 million shares or pre-funded warrants and 12.325 million warrants at price of $3.25 per share and associated warrants. \n\n\n  The company is offering the securities pursuant to a registration statement filed Monday. \n\n\nOn Tuesday, Aptevo reported a standby equity-purchase agreement with Yorkville Advisors for up to $25 million. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 18, 2025 13:34 ET (17:34 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}